About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Boan Biotech to Present New Preclinical Data for CD3/CEA BsAb at AACR 2021

News

Boan Biotech, a holding subsidiary of Luye Pharma Group, will present an abstract about the preclinical data on its CD3/CEA bispecific antibody program at the American Association for Cancer Research (AACR) Annual Meeting 2021. The historic ...

March 30,2021

Rykindo® Launched! First Innovative Microsphere Formulation Independently Developed in China Brings Increased Clinical Benefits to Schizophrenia ...

Rykindo is an extended release microspheres injection developed by Luye Pharma on its world-leading microsphere technology platform and represents an innovative new therapy for the treatment of schizophrenia. It is the first innovative microsphere formulation independently developed and owned by a Chinese company, including all related intellectual property, and is currently undergoing global registration. It is also China's first independently developed second-generation long-acting injectable antipsychotic. The launch of Rykindo® brings new hope for societal reintegration to around ten million schizophrenia patients in China.

March 27,2021

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company